These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 19821497

  • 21. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 22. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
    Aneknan P, Kukongviriyapan V, Prawan A, Kongpetch S, Sripa B, Senggunprai L.
    Asian Pac J Cancer Prev; 2014 Jul; 15(12):5071-6. PubMed ID: 24998588
    [Abstract] [Full Text] [Related]

  • 23. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [Abstract] [Full Text] [Related]

  • 24. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    LaRocca RV, Hicks MD, Mull L, Foreman B.
    J Gastrointest Cancer; 2007 Apr; 38(2-4):154-6. PubMed ID: 19089671
    [Abstract] [Full Text] [Related]

  • 25. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
    Zheng T, Hong X, Wang J, Pei T, Liang Y, Yin D, Song R, Song X, Lu Z, Qi S, Liu J, Sun B, Xie C, Pan S, Li Y, Luo X, Li S, Fang X, Bhatta N, Jiang H, Liu L.
    Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
    Lozano E, Macias RIR, Monte MJ, Asensio M, Del Carmen S, Sanchez-Vicente L, Alonso-Peña M, Al-Abdulla R, Munoz-Garrido P, Satriano L, O'Rourke CJ, Banales JM, Avila MA, Martinez-Chantar ML, Andersen JB, Briz O, Marin JJG.
    Hepatology; 2019 Oct; 70(4):1246-1261. PubMed ID: 30972782
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
    Lu Z, Wang J, Zheng T, Liang Y, Yin D, Song R, Pei T, Pan S, Jiang H, Liu L.
    BMC Cancer; 2014 Oct 25; 14():783. PubMed ID: 25344679
    [Abstract] [Full Text] [Related]

  • 31. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.
    Cancer Biol Ther; 2009 Dec 25; 8(24):2406-16. PubMed ID: 20038816
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.
    Mol Cancer Ther; 2008 Apr 25; 7(4):890-6. PubMed ID: 18413802
    [Abstract] [Full Text] [Related]

  • 37. Myricetin ameliorates cytokine-induced migration and invasion of cholangiocarcinoma cells via suppression of STAT3 pathway.
    Tuponchai P, Kukongviriyapan V, Prawan A, Kongpetch S, Senggunprai L.
    J Cancer Res Ther; 2019 Apr 25; 15(1):157-163. PubMed ID: 30880773
    [Abstract] [Full Text] [Related]

  • 38. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
    Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D.
    Mol Med; 2012 Feb 10; 18(1):19-28. PubMed ID: 21979753
    [Abstract] [Full Text] [Related]

  • 39. Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation.
    Huyen NT, Prachayasittikul V, Chan-On W.
    J Hepatobiliary Pancreat Sci; 2016 Jul 10; 23(7):397-405. PubMed ID: 27107220
    [Abstract] [Full Text] [Related]

  • 40. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
    Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S.
    Mol Cell Biol; 2007 Aug 10; 27(15):5499-513. PubMed ID: 17548474
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.